Featured Research

from universities, journals, and other organizations

Missing Chromosome Predicts Brain Tumor Patients' Response To Treatment

Date:
February 21, 2008
Source:
American Academy of Neurology
Summary:
People with a highly aggressive type of brain tumor who are missing a specific chromosome live longer and respond better to the chemotherapy drug temozolomide than people without this genetic abnormality. Gliomatosis cerebri is a rare type of brain tumor that is difficult to diagnosis, cannot be operated on, and has an extremely variable prognosis.

People with a highly aggressive type of brain tumor who are missing a specific chromosome live longer and respond better to the chemotherapy drug temozolomide than people without this genetic abnormality, according to new research.  Gliomatosis cerebri is a rare type of brain tumor that is difficult to diagnosis, cannot be operated on, and has an extremely variable prognosis.

"Our findings will help doctors better predict who will respond best to temozolomide, which has recently been proposed as a new treatment for gliomatosis cerebri," said Marc Sanson, MD, PhD, with INSERM, the French government health agency, in Paris, France. "Before now, we weren't sure which factors influenced how well a person with this type of brain tumor would respond to the treatment."

For the study, 25 people with gliomatosis cerebri underwent genetic testing and received monthly treatments of temozolomide for up to two years.

The study found nearly all of the participants who were missing chromosome 1p and 19q had a higher response rate to temozolomide and lived longer.

"Eighty-eight percent of those people with this genetic signature responded well to temozolomide compared to only 25 percent of those people without the genetic abnormality," said Sanson. "In addition, those without 1p and 19q survived an average five and half years compared to only 15 months for the group with intact 1p and 19q. Those missing 1p and 19q also had more months without the tumor further progressing. Therefore, temozolomide is now our first choice of treatment for patients with gliomatosis cerebri, especially when missing chromosomes 1p and 19q."

This research was published in the February 19, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology. The study was supported by a grant from the Delegation for Clinical Research in Paris.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "Missing Chromosome Predicts Brain Tumor Patients' Response To Treatment." ScienceDaily. ScienceDaily, 21 February 2008. <www.sciencedaily.com/releases/2008/02/080218172535.htm>.
American Academy of Neurology. (2008, February 21). Missing Chromosome Predicts Brain Tumor Patients' Response To Treatment. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2008/02/080218172535.htm
American Academy of Neurology. "Missing Chromosome Predicts Brain Tumor Patients' Response To Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/02/080218172535.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) — After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) — A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) — Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) — Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins